No statistical differences were found in serum VEGF levels between the other angiosarcoma patients (cases 3–11) in whom the p53 gene point mutation was not detected; these patients include those without metastasis (153 ± 70 pg ml⁻¹, range 65–223, n = 4), those with metastasis to parotid lymph nodes (166 ± 70 pg ml⁻¹, range 62–244, n = 6), and those with remote metastasis (119 ± 101 pg ml⁻¹, range 7–269, n = 7) (Fig. 1).

Because of serious heart failure, the patient who had detectable p53 gene point mutation (case 1) was treated with local radiation therapy alone. The other patients were treated with surgery, radiation therapy, local or systemic administration of recombinant interleukin-2 (IL-2), and immunotherapy using IL-2 and IL-2-activated lymphocytes. The effect of these treatments may have contributed to the serum VEGF levels. Therefore, serum VEGF levels may not be correlated with clinical course in most cases of angiosarcomas without p53 gene mutation.

REFERENCES


Generalized Pustulosis and Severe Tubulointerstitial Nephropathy as Manifestations of Carbamazepine Hypersensitivity Syndrome

David Moreno-Ramírez¹, Begona García-Bravo¹, Antonio Rodríguez-Pichardo¹, Clotilde Ríos Camacho² and Francisco Camacho Martínez¹

Departments of ¹Dermatology and ²Nephrology, University Hospital “Virgen Macarena”, Seville, Spain.

E-mail: camachoelp@medynet.com

Accepted 3 June, 2002.

Sir,

Anticonvulsant hypersensitivity syndrome (AHS) is a multisystemic disorder with cutaneous changes and typical blood abnormalities that may be triggered by any of the aromatic antiepileptic drugs (1, 2). We present the case of a patient who, following carbamazepine treatment, developed AHS with major cutaneous and systemic manifestations that are not common in the context of this syndrome.

CASE REPORT

A 26-year-old woman was referred to our department for evaluation of a 10-day history of malaise, fever of up to 40°C and a generalized exanthem. The patient had been on carbamazepine therapy (400 mg daily) for 1 month because of temporal epileptic seizures. She reported no previous history of drug allergies.

Examination revealed a red-violet exanthem involving the trunk, extremities, palms and soles; the face was severely affected, accompanied by mild oedema. A large number of pinhead-sized pustules were observed on her face and upper back with an intensely erythematous skin (Fig. 1). A biopsy taken from these pustular lesions revealed follicular and non-follicular intraepidermic spongiform pustules, with a perivascular infiltration of lymph cells and eosinophils in the upper dermis. Vasculitis was absent. These histological changes were consistent with an acute generalized exanthematous pustulosis.

Systemic examination revealed a deteriorated overall condition of the patient, fever, hepatomegaly and swollen bilateral inguinal lymph nodes. The first laboratory tests disclosed eosinophilia (13.5%) and elevated liver function tests: aspartate aminotransferase 63 U/l (0–37 U/l), alanine aminotransferase 262 U/l (0–40 U/l) and gamma glutamyltranspeptidase 335 U/l (11–49 U/l).

In view of the clinical and histological changes, we considered the case to be related to carbamazepine, so
The patient was finally discharged from hospital 30 days after admission.

Once completely recovered, the patient was patch-tested with carbamazepine 0.1%, 1% and 10% in petrolatum, showing positive results. Seven months later, she developed a morbilliform exanthem after 4 weeks of treatment with phenytoin, but on this occasion the eruption disappeared with no systemic involvement after withdrawal of the drug.

DISCUSSION

Differential diagnosis of generalized pustular eruptions in adults includes subcorneal pustular dermatosis, eosinophilic pustular folliculitis, pustular psoriasis and acute generalized exanthematous pustulosis, among others.

AHS is one of the adverse effects of aromatic antiepileptic drugs such as phenytoin, carbamazepine, phenobarbital and primidone. Most cases have been related to phenytoin and carbamazepine because they are more widely used (1, 2). The true incidence of this syndrome is not well established because of the lack of reliable diagnostic criteria. Nevertheless, among patients on carbamazepine treatment the incidence may range from 1:1000 to 1:10000.

Although the pathogenesis is not well understood, the most accepted hypotheses suggest the inability of these patients to detoxify certain oxides, which are formed from the metabolism of anticonvulsants. Constitutional factors, HHV-6 infection and a specific T-cell response, are also being discussed as possible pathogenic mechanisms (3).

AHS clinical manifestations usually start 2 to 8 weeks after the initiation of anticonvulsant therapy and consist of fever, skin rash, lymphadenopathy, hepatopathy and eosinophilia (4, 5). Cutaneous changes are present in up to 87% of the patients with AHS, and usually consist of a morbilliform exanthem, although some cases of exanthematous pustulosis have been reported (1, 4). Fever is the most common systemic complaint and the liver is the internal organ most frequently affected in this syndrome, with an incidence of 100% and 51%, respectively. Hepatic changes range from transitory high transaminase levels to fulminant hepatic failure. This patient showed the mildest form of liver impairment. Renal involvement is not common, but when it is present a prerenal failure secondary to hypovolaemia is the most frequent clinical feature. Our patient developed severe parenchymatous renal failure which, although not common, has been described in isolated cases of AHS (1, 2, 6).

Treatment consists of discontinuing the suspected drug, regulation of nutritional and fluid imbalance and the management of possible complications, which in this patient even required haemodialysis. Unlike our case, the prognosis is good for most patients, with
spontaneous healing a few weeks after withdrawal of the drug (1, 2).

An essential issue to take into account in these patients is the high prevalence of cross-reactivity between the different aromatic anticonvulsants, which in some reports is up to 80% and makes the choice of an alternative drug for these patients difficult. Although valproic acid, lamotrigine and vigabatrin are considered the safest antiepileptic drugs for these patients, some cases of hypersensitivity anticonvulsant syndrome have been reported to be triggered by them (1, 2).

In conclusion, we present an extremely unusual case of AHS, since both pustular exanthem and severe tubulointerstitial nephropathy are exceptional in the context of this syndrome, especially if we consider their combined appearance.

REFERENCES

A Four-Year History of Pruriginous Erythroderma Leading to the Diagnosis of Idiopathic Hypereosinophilic Syndrome

David Launay1, Benoît Catteau1, Ariane Dubost-Brama1, Monique Capron2, Frédéric Piette1 and Emmanuel Delaporte1*
1Department of Dermatology, Claude-Huriez Hospital, 1, Place de Verdun, 59037 Lille, France, and 2INSERM 545, Institut Pasteur de Lille, Lille, France. *E-mail: edelaporte@chru-lille.fr
Accepted April 22, 2002.

Sir,

Idiopathic hypereosinophilic syndrome (IHS) is characterized by persistent eosinophilia (above 1.5 × 10^9/l for more than 6 months) of unknown origin in association with dysfunction of one or more organs due to tissue infiltration by eosinophils (1). Cutaneous, cardiac, neurologic and/or pulmonary manifestations are often observed. Among the skin lesions, erythroderma is a rare complication of IHS and has only been reported in a few cases (2–6).

CASE REPORT

In December 1994, a 67-year-old man with no history of atopy or current medication was referred due to severely itching erythroderma of a few weeks’ duration (Fig. 1), small bullae on the upper limbs (Fig. 2), a palmo-plantar keratoderma and slight edema of the skin. White cell count was 12.2 × 10^9/l with 9% eosinophils (1.1 × 10^9/l, normal range 0–0.5). A skin biopsy showed non-specific, mild vasculitis with eosinophils. Topical treatment was not sufficiently effective but prednisone (1 mg/kg daily) relieved the skin lesions and pruritus, with normalization of blood eosinophilia. Between April 1996 and March 1997 the patient’s symptoms relapsed, with blood eosinophilia ranging between 1.5 × 10^9/l and 4.0 × 10^9/l. Short courses of prednisone temporarily improved the skin lesions.

In June 1997 the patient was admitted to our

REFERENCES

A Four-Year History of Pruriginous Erythroderma Leading to the Diagnosis of Idiopathic Hypereosinophilic Syndrome

David Launay1, Benoît Catteau1, Ariane Dubost-Brama1, Monique Capron2, Frédéric Piette1 and Emmanuel Delaporte1*
1Department of Dermatology, Claude-Huriez Hospital, 1, Place de Verdun, 59037 Lille, France, and 2INSERM 545, Institut Pasteur de Lille, Lille, France. *E-mail: edelaporte@chru-lille.fr
Accepted April 22, 2002.

Sir,

Idiopathic hypereosinophilic syndrome (IHS) is characterized by persistent eosinophilia (above 1.5 × 10^9/l for more than 6 months) of unknown origin in association with dysfunction of one or more organs due to tissue infiltration by eosinophils (1). Cutaneous, cardiac, neurologic and/or pulmonary manifestations are often observed. Among the skin lesions, erythroderma is a rare complication of IHS and has only been reported in a few cases (2–6).

CASE REPORT

In December 1994, a 67-year-old man with no history of atopy or current medication was referred due to severely itching erythroderma of a few weeks’ duration (Fig. 1), small bullae on the upper limbs (Fig. 2), a palmo-plantar keratoderma and slight edema of the skin. White cell count was 12.2 × 10^9/l with 9% eosinophils (1.1 × 10^9/l, normal range 0–0.5). A skin biopsy showed non-specific, mild vasculitis with eosinophils. Topical treatment was not sufficiently effective but prednisone (1 mg/kg daily) relieved the skin lesions and pruritus, with normalization of blood eosinophilia. Between April 1996 and March 1997 the patient’s symptoms relapsed, with blood eosinophilia ranging between 1.5 × 10^9/l and 4.0 × 10^9/l. Short courses of prednisone temporarily improved the skin lesions.

In June 1997 the patient was admitted to our

REFERENCES